Lingzhuo Kong1 · Yiqing Chen1 · Yuting Shen1 · Danhua Zhang1 · Chen Wei1 · Jianbo Lai1,2,3,4,5 · Shaohua Hu1,2,3,4,51 Department of Psychiatry, the First Afliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
2 The Key Laboratory of Mental Disorder Management in Zhejiang Province, Hangzhou 310003, China
3 Brain Research Institute of Zhejiang University, Hangzhou 310003, China
4 Zhejiang Engineering Center for Mathematical Mental Health, Hangzhou 310003, China
5 Department of Neurobiology, NHC and CAMS Key Laboratory of Medical Neurobiology, School of Brain Science and Brian Medicine, and MOE Frontier Science Center for Brain Science and Brain-machine Integration, Zhejiang University School of Medicine, Hangzhou 310003, China
Abstract
With the advancements in gene sequencing technologies, including genome-wide association studies, polygenetic risk scores, and high-throughput sequencing, there has been a tremendous advantage in mapping a detailed blueprint for the genetic model of bipolar disorder (BD). To date, intriguing genetic clues have been identified to explain the development of BD, as well as the genetic association that might be applied for the development of susceptibility prediction and pharmacogenetic intervention. Risk genes of BD, such as CACNA1C, ANK3, TRANK1, and CLOCK, have been found to be involved in various pathophysiological processes correlated with BD. Although the specific roles of these genes have yet to be determined, genetic research on BD will help improve the prevention, therapeutics, and prognosis in clinical practice. The latest preclinical and clinical studies, and reviews of the genetics of BD, are analyzed in this review, aiming to summarize the progress in this intriguing field and to provide perspectives for individualized, precise, and effective clinical practice.
Keywords
Bipolar disorder; Genetics; Risk gene; Genome-wide association study; Sequencing technology
